Please login to read the full article.
Scrip Regulatory Affairs
EU paediatric studies: can fines succeed where carrots and sticks have not?
22 September 2011
Ian Schofield
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EMA Q&As elaborate on paediatric use marketing authorisations and PIPs
- EU industry cautious about proposed penalties under pharmacovigilance and paediatric frameworks
- US user fee bill advances in Senate; House session postponed
- European court ruling means firms could face greater paediatric studies obligation beyond intended indication
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
